Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

27/06/2017 ​Barcelona Synchrotron Park’s sustainable brownfield restoration program presented at AquaConSoil 2017 21/06/2017 Catalonia confirms itself as pole of attraction for foreign investments 15/06/2017 Construction of the Natura Bissé’s new world headquarters is well on its way 06/06/2017 ​Walk in the Park: the biodiversity routes await you 31/05/2017 UAB second most innovative university in Spain 24/05/2017 PRUAB: 10 years in strengthening relationships between research and business fabric
16 17 18 19 20 21 22 23 24 25 26